vTv Therapeutics Inc. Class A (VTVT)
$35.66
$-0.94
(-2.57%)
As on 21-May-2026 11:09EDT
Market cap
$144 Mln
Revenue (TTM)
$37 Mln
P/E Ratio
--
P/B Ratio
1.6
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-2.1
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$--
-
Face value
--
-
Shares outstanding
3,938,654
10 Years Aggregate
CFO
$-282.21 Mln
EBITDA
$-292.86 Mln
Net Profit
$-197.83 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
vTv Therapeutics Inc. Class A (VTVT)
| -10.8 | -5.5 | 4.0 | 71.9 | -0.7 | -19.0 | -16.3 |
|
BSE Sensex
| -11.2 | -4.2 | -9.2 | -7.4 | 6.8 | 8.7 | 11.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
vTv Therapeutics Inc. Class A (VTVT)
| 189.6 | 19.9 | -56.6 | -33.4 | -46.5 | 9.4 | -35.8 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
vTv Therapeutics Inc. Class A (VTVT)
|
35.7 | 143.7 | 36.8 | 2.3 | -5.3 | 6.5 | -- | 1.6 |
| 74.8 | 10,307.9 | 622.0 | -300.9 | -30.1 | -62 | -- | 17.6 | |
| 242.4 | 14,777.7 | 867.5 | 506.6 | -2.8 | -- | 27.2 | 25.9 | |
| 78.2 | 10,379.7 | 105.8 | -829.6 | -715.0 | -- | -- | 60.5 | |
| 49.4 | 12,233.5 | 2,375.5 | 833.4 | 40.8 | 40.7 | 16.1 | 6.5 | |
| 119.4 | 13,020.0 | 1,080.2 | -433.2 | -39.8 | -- | -- | 60.9 | |
| 300.0 | 8,785.0 | 417.3 | 225.0 | 42.8 | 18.6 | 39.9 | 6.8 | |
| 507.6 | 11,800.4 | 1,132.5 | -309.4 | -25.5 | -52.9 | -- | 21.7 | |
| 422.3 | 11,992.5 | 2,678.3 | 460.4 | 21.1 | 103.2 | 26.4 | 20.0 | |
| 342.0 | 8,938.2 | 0.0 | -326.5 | -- | -37.2 | -- | 6.3 |
Shareholding Pattern
View DetailsAbout vTv Therapeutics Inc. Class A (VTVT)
vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an... orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a range of molecules across various indications for chronic diseases. It has a license agreement Newsoara Biopharma Co., Ltd. to develop and commercialize phosphodiesterase type 4 inhibitors program. vTv Therapeutics Inc. was incorporated in 2015 and is headquartered in High Point, North Carolina. Address: 3980 Premier Drive, High Point, NC, United States, 27265 Read more
-
CEO, President & Director
Mr. Paul J. Sekhri M.Sc.
-
CEO, President & Director
Mr. Paul J. Sekhri M.Sc.
-
Headquarters
High Point, NC
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for vTv Therapeutics Inc. Class A (VTVT)
What is the current share price of vTv Therapeutics Inc Class A (VTVT) Today?
The share price of vTv Therapeutics Inc Class A (VTVT) is $35.66 (NASDAQ) as of 21-May-2026 11:09 EDT. vTv Therapeutics Inc Class A (VTVT) has given a return of -0.68% in the last 3 years.
What is the current PB & PE ratio of vTv Therapeutics Inc Class A (VTVT)?
Since, TTM earnings of vTv Therapeutics Inc Class A (VTVT) is negative, P/E ratio is not available.
The P/B ratio of vTv Therapeutics Inc Class A (VTVT) is 1.60 times as on 20-May-2026, a 63 discount to its peers’ median range of 4.31 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-11.86
|
4.96
|
|
2024
|
-4.49
|
6.79
|
|
2023
|
-1.14
|
-0.93
|
|
2022
|
-0.07
|
-0.12
|
|
2021
|
-0.15
|
-0.20
|
What is the 52 Week High and Low of vTv Therapeutics Inc Class A (VTVT)?
The 52-week high and low of vTv Therapeutics Inc Class A (VTVT) are Rs 44.00 and Rs 14.00 as of 21-May-2026.
What is the market cap of vTv Therapeutics Inc Class A (VTVT)?
vTv Therapeutics Inc Class A (VTVT) has a market capitalisation of $ 144 Mln as on 20-May-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in vTv Therapeutics Inc Class A (VTVT)?
Before investing in vTv Therapeutics Inc Class A (VTVT), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.